Dare Bioscience (NASDAQ:DARE) Stock Price Up 8.9%

Shares of Dare Bioscience Inc (NASDAQ:DARE) rose 8.9% on Friday . The company traded as high as $0.86 and last traded at $0.86, approximately 109,400 shares changed hands during mid-day trading. A decline of 80% from the average daily volume of 558,394 shares. The stock had previously closed at $0.79.

DARE has been the subject of a number of research analyst reports. Aegis initiated coverage on Dare Bioscience in a research report on Thursday, August 22nd. They issued a “buy” rating for the company. Maxim Group initiated coverage on Dare Bioscience in a research report on Monday. They issued a “buy” rating and a $3.00 price target for the company. Finally, ValuEngine upgraded Dare Bioscience from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd.

The stock has a market cap of $13.48 million, a PE ratio of -0.79 and a beta of 1.89. The business has a 50-day moving average of $0.79 and a 200 day moving average of $0.95.

Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). On average, analysts expect that Dare Bioscience Inc will post -0.88 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Dare Bioscience stock. Geode Capital Management LLC increased its stake in shares of Dare Bioscience Inc (NASDAQ:DARE) by 80.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,470 shares of the biotechnology company’s stock after purchasing an additional 47,170 shares during the quarter. Geode Capital Management LLC owned approximately 0.92% of Dare Bioscience worth $73,000 as of its most recent filing with the Securities and Exchange Commission. 5.11% of the stock is owned by institutional investors and hedge funds.

About Dare Bioscience (NASDAQ:DARE)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

See Also: Buyback

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.